New EndoTool IV Data Presented at AACE Demonstrates Near Elimination of Severe Hypoglycemia Across 19 Hospitals Glooko, Inc., a globally integrated digital health company dedicated to improving diabetes management and…
Anaxiom Reports Initial First-in-Human Clinical Results for Novel Minimally Invasive Obesity Device, Progresses Toward U.S. Early Feasibility Study Anaxiom Corporation, a clinical-stage innovator focused on developing minimally invasive solutions for…
HealthPartners Highlights Ongoing Progress, Key Priorities, and Future Actions to Advance Simpler, More Affordable Health Care Amid a persistent rise in both medical and pharmacy costs, HealthPartners is stepping up…
GE HealthCare Doses First Patient in Phase 2/3 LUMINA Trial of Manganese-Based MRI Contrast Agent Under FDA Fast Track Status, Advancing Imaging Innovation Pipeline GE HealthCare has announced a major…
Ironwood Pharmaceuticals to Present Real-World Clinician Insights on Total Parenteral Nutrition Burden in Short Bowel Syndrome at Digestive Disease Week® 2026 Ironwood Pharmaceuticals, Inc. has announced that it will present…
Bausch + Lomb Publishes Review on B Vitamins and Their Role in Reducing Risk and Progression of Age-Related Macular Degeneration Bausch + Lomb Corporation has announced the publication of a…
BNB Plus Corp. Finalizes Landmark $1.2 Million LineaDNA™ Order BNB Plus Corp. has announced a significant operational milestone through its biopharmaceutical subsidiary, LineaRx, Inc., which has successfully completed the largest…
CatalYm Initiates Phase 2/3 Trial of Visugromab in Cancer Cachexia with First Patient Dosed CatalYm has announced an important milestone in its clinical development pipeline with the dosing of the…
Merz Group Participates in the “Made for Germany” Initiative The Merz Group has taken a significant step in reinforcing its commitment to Germany’s industrial and economic future by joining the…
AbbVie Chooses North Carolina as Site for $1.4 Billion Advanced Manufacturing Facility AbbVie has unveiled an ambitious new chapter in its long-term growth strategy with the announcement of a $1.4…
IMAAVY® (nipocalimab-aahu) Demonstrates Durable, Over Two-Year Disease Control Across a Broad gMG Patient Population Johnson & Johnson has unveiled new clinical findings highlighting the long-term efficacy and safety of IMAAVY®…
Late-Breaking PRESERVE Trial Findings Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation XVIVO, a global medical technology company specializing in organ preservation and transplantation, has announced encouraging late-breaking preliminary results…